Immune monitoring after rituximab for ANCA vasculitis
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at how the immune system changes after treatment with rituximab for ANCA-associated vasculitis, a rare autoimmune disease that causes inflammation of blood vessels. The goal is to better understand the effects of this maintenance therapy, which may help improve future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are covered by the French social security system.
- You have ANCA-associated vasculitis with positive anti-PR3 or anti-MPO antibodies.
- You are scheduled to receive rituximab maintenance therapy (500 mg every 6 months) after a flare or relapse.
- You do not have end-stage kidney disease or an active cancer (other than skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood test markers that may help diagnose vasculitis and predict how it may go. You may be offered additional blood sampling if you have certain active vasculitis conditions.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This study collects and stores health information and possibly samples from people diagnosed with ANCA-associated vasculitis to help researchers learn more about the disease. It may help future studies, but it is mainly focused on collection rather than testing a new treatment.
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Hear when a new Vasculitis Associated With Anti-neutrophil Cytoplasmic Antibodies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.